OOIR: Observatory of International Research

Papers

(The TQCC of Current Opinion in Gastroenterology is 6. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)

Article	Citations
Metabolic dysfunction-associated fatty liver disease: a year in review	50
Peutz-Jeghers syndrome	43
Breastfeeding and the developmental origins of mucosal immunity: how human milk shapes the innate and adaptive mucosal immune systems	41
Gut microbiota and sepsis: from pathogenesis to novel treatments	38
New targets in inflammatory bowel disease therapy: 2021	37
Why antibiotics should not be used to treat Shiga toxin-producing Escherichia coli infections	25
Gastrointestinal symptoms in COVID-19: the long and the short of it	24
Role of gut–kidney axis in renal diseases and IgA nephropathy	23
Primary biliary cholangitis: pathogenic mechanisms	23
Diabetes in chronic pancreatitis: risk factors and natural history	23
Advances in the treatment of gastric cancer: 2020–2021	21
The prevention of gastric cancer by Helicobacter pylori eradication	20
The rise of antibiotic resistance in Campylobacter	20
Diagnosis and management of Clostridioides difficile infection in patients with inflammatory bowel disease	20
Diet and cancer of the esophagus and stomach	20
Faecal microbiota replacement to eradicate antimicrobial resistant bacteria in the intestinal tract – a systematic review	19
Dysregulated lipid metabolism in colorectal cancer	18
Primary biliary cholangitis: treatment	17
Bone loss in patients with inflammatory bowel disease: cause, detection and treatment	16
Social media in inflammatory bowel disease: the patient and physician perspective	15
Can SARS-CoV-2 be transmitted via faeces?	15
Diet and carcinogenesis of gastric cancer	14
Severe acute respiratory syndrome coronavirus-2-associated cholangiopathies	13
Advances in cirrhotic cardiomyopathy	13
The future of telemedicine and wearable technology in IBD	13

Single-use duodenoscopes: where are we and where are we going?	13
Advancing flexible endoscopy to natural orifice transluminal endoscopic surgery	13
The impact of inflammatory bowel disease on women's lives	13
The potential of microbiome replacement therapies for Clostridium difficile infection	12
Should high-fiber diets be recommended for patients with inflammatory bowel disease?	12
Type 3 autoimmune pancreatitis (immune checkpoint inhibitor-induced pancreatitis)	12
The role of bariatric surgery in the management of nonalcoholic steatohepatitis	12
Noninvasive assessment oesophageal varices: impact of the Baveno VI criteria	12
Distinguishing diabetes secondary to pancreatic diseases from type 2 diabetes mellitus	11
Current endoscopic approaches to biliary strictures	11
Mesenchymal stem cell therapy for liver disease: current status and future perspectives	11
Immunotherapy in cholangiocarcinoma	10
Diet as a treatment for inflammatory bowel disease: is it ready for prime time?	10
The role of magnetic sphincter augmentation in the treatment of gastroesophageal reflux disease	10
Advances in the genetics of nonalcoholic fatty liver disease	10
Management of refractory inflammatory bowel disease	9
Macronutrients, microbiome and precision nutrition	9
Novel treatment options for acute hepatic porphyrias	9
Neoadjuvant therapy in pancreatic cancer: a review and update on recent trials	9
The debate in the diagnosis of coeliac disease – time to go ‘no-biopsy’?	9
Updated strategies in the management of acute variceal haemorrhage	9
Cellular senescence in the cholangiopathies	9
Macrophages in cholangiopathies	9
Mechanisms of autoimmune hepatitis	9
Painful chronic pancreatitis - new approaches for evaluation and management	8
Diabetes and pancreatic cancer: recent insights with implications for early diagnosis, treatment and prevention	8
Celiac disease: clinical update	8
Hepatitis E virus: has anything changed?	8
Complications of chronic pancreatitis in children	8
Comparative efficacy trials in inflammatory bowel disease: current and future implications for practice	8
A review of deep learning and radiomics approaches for pancreatic cancer diagnosis from medical imaging	8
Nutritional consequences of bariatric surgery – prevention, detection and management	8
Impact of bariatric surgery on gastroesophageal reflux disease and esophageal motility	8
Drug-induced bile duct injury: new agents, new mechanisms	8
Multidisciplinary management of perianal Crohn's disease	7
Endohepatology – current status	7
Implantation of transjugular intrahepatic portosystemic shunt (TIPS): indication and patient selection	7
Novel treatments for alcoholic hepatitis	7
Dietary interventions and irritable bowel syndrome – what really works?	7
Third space endoscopy: the future of treating gastrointestinal dysmotility	7
Esophageal afferent innervation and its role in gastro-esophageal reflux disease symptoms	7
Gastroparesis	7
Acute-on-chronic liver failure: update on pathogenesis, therapeutic targets, predictive models, and liver transplantation	7
Impact of gastroesophageal reflux disease on idiopathic pulmonary fibrosis and lung transplant recipients	7
Optimal inflammatory bowel disease management during the global coronavirus disease 2019 pandemic	7
Endoscopic methods for the detection and treatment of gastric cancer	7
Autoimmune hepatitis: from immunopathogenesis to diagnostic and therapeutic innovation	7
Early detection of pancreatic cancer: current state and future opportunities	7
Recent insights on functional heartburn and reflux hypersensitivity	7
Probiotics in irritable bowel syndrome and inflammatory bowel disease: review of mechanisms and effectiveness	7

Role of albumin in the treatment of decompensated liver cirrhosis	7
Molecular targets and the use of biologics in the management of small bowel fibrosis in inflammatory bowel disease	7
Nutrition and diet in inflammatory bowel disease	7
Implications of Paneth cell dysfunction on gastrointestinal health and disease	7
Small bowel radiology	7
Management of the patient with esophagogastric junction outflow obstruction	6
Mucosal immunity in primary sclerosing cholangitis: from the bowel to bile ducts and back again	6
Positioning biologics and small molecules in the management of moderate to severe ulcerative colitis	6
Demographics and risk factors for pediatric recurrent acute pancreatitis	6
The role of the allergist in the management of eosinophilic esophagitis	6
Statins for treatment of chronic liver disease	6
Precision medicine: how multiomics will shape the future of inflammatory bowel disease?	6
The gut-liver axis in cholangiopathies: focus on bile acid based pharmacological treatment	6
The spectrum of diabetes in acute and chronic pancreatitis	6
Positioning biologics in the management of moderate to severe Crohn's disease	6
Bile acids as metabolic regulators: an update	6